Andarine (S4)
Aliases: S-4 · Andarine · GTx-007
Last verified: 2026-09-23
The short version
An early SARM — moderate anabolic strength, popular for cutting. Known for its signature side effect: yellow-tinted vision and night-vision problems. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical + Phase I; development discontinued. Status: discontinued. Not approved; WADA-banned (S1).
Identity & type
- Molecular type
- SARM
- Origin
- An early SARM — moderate anabolic strength, popular for cutting.
Mechanism of action
Partial AR agonist; also binds ocular receptors (side effect).
not confirmed in humans
Dosing & routes
Official / clinical context
Development was abandoned; no active regulatory document exists. There are no official indications.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Community: 25–50 mg/day (5 days on/2 off). Definition/vascularity in deficit phases; the characteristic "yellow" tint and slower dark adaptation at higher doses — reversible after discontinuation.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Definition/vascularity in deficit phases; the characteristic "yellow" tint and slower dark adaptation at higher doses — reversible after discontinuation.
Protocol — official vs community
Official / label
No approved product. Development discontinued (vision side effects).
Duration: —
Its metabolites bind retinal androgen receptors — the only SARM with a signature visual side effect.
Community (anecdotal)
25–50 mg oral daily, split AM/PM.
- Cycle:
- 6–8 weeks.
- Break:
- 6+ weeks.
The yellow-tint vision side is the community's self-limiting brake on dosing.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical + Phase I; development discontinued.
Preclinical evidence
Preclinical + Phase I; development discontinued.
Known risks
- Visual disturbances (reversible), suppression, liver enzymes.characterized
- WADA prohibition (S1 anabolic agents)characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.